Claims
- 1. An isolated nucleic acid molecule consisting of a nucleotide sequence selected from the group consisting of SEQ ID Nos. 8, 13, 18-19, 41, 51, and 319.
- 2. An isolated nucleic acid molecule consisting of a nucleotide sequence at least 80% identical to a sequence selected from the group consisting of SEQ ID Nos. 8, 13, 18-19, 41, 51, and 319.
- 3. An expression vector, capable of replicating in at least one of a prokaryotic cell and eukaryotic cell, consisting of vector sequences and the nucleic acid of claim 1.
- 4. The expression vector of claim 3, further consisting of a transcriptional regulatory sequence operably linked to said nucleotide sequence so as to render said expression vector capable of replicating in said at least one of a prokaryotic cell and eukaryotic cell.
- 5. A host cell transfected with the expression vector of claim 3.
- 6. A probe/primer consisting of a nucleotide sequence of 30 consecutive nucleotides of a sequence selected from the group consisting of SEQ ID Nos. 8, 13, 18-19, 41, 51, and 319.
- 7. The probe/primer of claim 6, wherein said probe/primer is labeled with a label group.
- 8. The probe/primer of claim 7, wherein said label group being selected from radioisotopes, fluorescent compounds, enzymes, and enzyme co-factors.
- 9. A test kit for determining the phenotype of transformed cells, conprising the probe/primer of claim 7 and suitable packaging materials therefore.
- 10. A pharmaceutical composition comprising a nucleic acid molecule consisting of a sequence selected from the group consisting of SEQ ID Nos. 8, 13, 18-19, 41, 51, and 319.
- 11. An isolated nucleic acid molecule consisting of a nucleotide sequence complementary to a nucleotide sequence selected from the group consisting of SEQ ID Nos. 8, 13, 18-19, 41, 51, and 319.
- 12. An isolated nucleic acid molecule consisting of a nucleotide sequence complementary to a nucleotide sequence which is at least 80% identical to a sequence selected from the group consisting of SEQ ID Nos. 8, 13, 18-19, 41, 51, and 319.
- 13. A probe/primer consisting of a nucleotide sequence complementary to 30 consecutive nucleotides of a sequence selected from the group consisting of SEQ ID Nos. 8, 13, 18-19, 41, 51, and 319.
- 14. A test kit for determining the phenotype of transformed cells, comprising the probe/primer of claim 13 and suitable packaging materials therefore.
- 15. A pharmaceutical composition comprising a nucleic acid molecule consisting of a nucleotide sequence complementary to a nucleotide sequence selected from the group consisting of SEQ ID Nos. 8, 13, 18-19, 41, 51, and 319.
RELATED APPLICATION INFORMATION
This application is based on Provisional Application Nos. 60/117,393, filed Jan. 27, 1999, and 60/098,639, filed Aug. 31, 1998, which are incorporated herein by reference in their entirety. This application is a continuation-in-part of application Ser. No. 09/328,111, filed on Jun. 8, 1999, which is incorporated by reference herein, in its entirety.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
4824776 |
Heller |
Apr 1989 |
|
5648478 |
Henderson |
Jul 1997 |
|
5686240 |
Schuchman et al. |
Nov 1997 |
|
Non-Patent Literature Citations (3)
Entry |
Hillier et al, “Generation and analysis of 280,000 human expressed sequence tags”, Genome Research, vol. 6, No.9, 1996, pp. 807-828.* |
Marra M et al, vd25a10.s1 Knowles Solter mouse 2 cell Mus musculus cDNA clone, GenCore version 4.5, Accession AA415444, The WashU-HHMI Mouse EST project, Oct. 16, 1997.* |
Tanaka et al, “Construction of a normalized directionally cloned cDNA library from adult heart and analysis of 3040 clones by partial sequencing”, Genomics 35, 1996, pp. 231-235. |
Provisional Applications (2)
|
Number |
Date |
Country |
|
60/117393 |
Jan 1999 |
US |
|
60/098639 |
Aug 1998 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09/328111 |
Jun 1999 |
US |
Child |
09/385982 |
|
US |